Daniela Abriss

Biochemistry, Genetics and Molecular Biology · Life Sciences

11h-index747citations18works22.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(6), Hemoglobinopathies and Related Disorders(5), Hemophilia Treatment and Research(5), CRISPR and Genetic Engineering(4), Prenatal Screening and Diagnostics(4)

Publications18 total

Gene editing without ex vivo culture evades genotoxicity in human hematopoietic stem cells
Cell stem cell·2024· 22 citedOpen Access
Gene editing without <i>ex vivo</i> culture evades genotoxicity in human hematopoietic stem cells
2023· 6 citedOpen Access
Induction of Fetal Hemoglobin and Reduction of Clinical Manifestations in Patients with Severe Sickle Cell Disease Treated with Shmir-Based Lentiviral Gene Therapy for Post-Transcriptional Gene Editing of BCL11A: Updated Results from Pilot and Feasibility Trial
Blood·2022· 9 cited
Combined +58 and +55 <i>BCL11A</i> enhancer Editing Yields Exceptional Efficiency, Specificity and HbF Induction in Human and NHP Preclinical Models
Blood·2021· 2 cited
Post-Transcriptional Genetic Silencing of <i>BCL11A</i> to Treat Sickle Cell Disease
New England Journal of Medicine·2020· 407 citedOpen Access
Preclinical Evaluation of a Novel Lentiviral Vector Driving Lineage-Specific BCL11A Knockdown for Sickle Cell Gene Therapy
Molecular Therapy — Methods & Clinical Development·2020· 67 citedOpen Access
Flipping the Switch: Initial Results of Genetic Targeting of the Fetal to Adult Globin Switch in Sickle Cell Patients
Blood·2018· 16 cited
Non-Clinical Efficacy and Safety Studies on G1XCGD, a Lentiviral Vector for <i>Ex Vivo</i> Gene Therapy of X-Linked Chronic Granulomatous Disease
Human Gene Therapy Clinical Development·2018· 36 cited
Influence of CC on FVIII stability in supernatant or plasma.
Figshare·2015Open Access
Next generation FIX muteins with FVIII‐independent activity for alternative treatment of hemophilia A
Journal of Thrombosis and Haemostasis·2014· 10 cited
CD133-targeted Gene Transfer Into Long-term Repopulating Hematopoietic Stem Cells
Molecular Therapy·2014· 24 citedOpen Access
Oral gene therapy for hemophilia B using chitosan‐formulated FIX mutants
Journal of Thrombosis and Haemostasis·2014· 18 citedOpen Access
Improving Hematopoietic Stem Cell Based Gene Therapy By Targeting CD133+ Cells
Blood·2013
Chemical Chaperones Improve Protein Secretion and Rescue Mutant Factor VIII in Mice with Hemophilia A
PLoS ONE·2012· 45 citedOpen Access
Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice
Blood·2011· 31 citedOpen Access
Transgene Loss and Changes in the Promoter Methylation Status as Determinants for Expression Duration in Nonviral Gene Transfer for Factor IX
Human Gene Therapy·2010· 20 cited
Factor VIII-eGFP fusion proteins with preserved functional activity for the analysis of the early secretory pathway of factor VIII
Thrombosis and Haemostasis·2009· 5 cited
Oxygen‐induced changes in hemoglobin expression in <i>Drosophila</i>
FEBS Journal·2008· 29 citedOpen Access

Frequent Co-authors

Christian Brendel(10), Myriam Armant(7), John Manis(7), Erhard Seifried(7), David A. Williams(6), Jörg Schüttrumpf(6), Peter Milanov(6), Danilo Pellin(5), Torsten Tonn(5), Erica B. Esrick(4), Patricia Quade-Lyssy(4), Manuel Grez(4), Marioara-Felicia Ciuculescu(4), Leslie Lehmann(3), Heather Daley(3), Olivier Nègre(3), Colleen Dansereau(3), Matthew M. Heeney(3), Stefanie Roth(3), Christopher Ungerer(3)